GSK has agreed to acquire RAPT Therapeutics, a South San Franciso, California-based, clinical-stage bio/pharmaceutical company, for $2.2 billion.  

The acquisition includes ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody, currently in Phase IIb clinical development for prophylactic protection against food allergens.    

The transaction gives GSK the global rights to the ozureprubart program, excluding Mainland China, Macau, Taiwan and Hong Kong. GSK will also be responsible for success-based milestone and royalty payments for ozureprubart owed to RAPT’s partner, Shanghai Jeyou Pharmaceutical Co. 

Under the agreement, GSK will pay RAPT Therapeutics shareholders $58.00 per share at closing for an estimated aggregate equity value of $2.2 billion. Net of cash acquired, GSK’s estimated upfront investment is $1.9 billion. The transaction is expected to close in the first quarter of 2026. 

Source: GSK